Diversified German drugmaker Bayer (BAYN: DE) has reported group sales of 13.8 billion euros ($14.9 billion) for the first quarter of 2024, a fall of around 0.6%, meeting expectations.
The firm’s pharmaceuticals business posted higher sales and earnings, with an increase of 3.9% to 4.4 billion euros, supported by strong performances for Nubeqa (darolutamide), a cancer drug, and Kerendia (finerenone), a kidney disease med.
Core earnings per share fell 4.4% to 2.82 euros, while net income stood at 2 billion euros for the quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze